Regeneron, New York’s largest biotechnology company, will invest approximately $1.8 billion over six years to expand its research, preclinical manufacturing and support facilities at its Westchester County campus in Tarrytown and create 1,000 new full-time, high-skill jobs in the Mid-Hudson Region over the next five years.
“The COVID-19 pandemic has highlighted the importance of continued and long-term investment in the biopharmaceutical industry, and Regeneron is proud to pursue life-changing science and technology from our labs and manufacturing facilities in New York State,” said Regeneron President and CEO Leonard S. Schleifer.
“In 2020 and 2021, the Regeneron team has worked tirelessly, bringing forward new treatments for people with COVID-19, Ebola, multiple forms of cancer and paediatric atopic dermatitis. As we expand our team and site, we look forward to bringing even more medical breakthroughs to patients in need.”
Assuming approvals from local authorities, Regeneron intends to substantially expand its research and development capabilities in Tarrytown, which will include the addition of new preclinical manufacturing and process development suites, laboratories and office space.
This project will encompass the design and construction and fit out of up to eight buildings, three parking garages and a central utility plant totalling approximately 900,000 square feet. Road infrastructure improvements will be necessary to support additional buildings at their existing Headquarters and R&D campus.
The project is planned to take place in 2 phases over 6 years.